Drug Profile
Research programme: glycine transporter 1 inhibitors - Curia
Alternative Names: AMR-GLY-1; AMR-GLY-3; AMR-GLY-6; GlyT-1 inhibitors - CuriaLatest Information Update: 13 Oct 2021
Price :
$50
*
At a glance
- Originator AMRI
- Developer Curia
- Class
- Mechanism of Action Glycine transporter 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Schizophrenia in USA (PO)
- 30 Sep 2016 Research programme: glycine transporter 1 inhibitors - AMRI is available for licensing as of 30 Sep 2016. http://www.amriglobal.com/partnering/
- 30 Sep 2016 Preclinical trials in Schizophrenia in USA (unspecified route) ((AMRI website, September 2016)